

FOREWORD

This volume is a valuable review of the literature of experimental and clinical studies of the effect of the adrenal corticoid and adrenotrophic pituitary hormones in the full range of human disease. The pendulum of opinion in the medical profession has swung from one of complete acceptance of the corticosteroids as a miraculous cure-all to the opposite extreme of complete disapproval as dangerous drugs. But now, the well-balanced belief of the profession is that these hormones have immense and extremely varied clinical usefulness.

Their mode of action and ultimate effect in pathology are by no means elucidated, but a few principles of therapeutic application are now recognizable. In many acute conditions, large doses may be given from the onset with valuable suppressive effect on inflammation, and with little danger of undesirable side effects, provided the term of therapy is measured in days.

In chronic conditions in which the physician has weighed the prognosis without the corticosteroids and decided that the morbidity and fatality to be faced require their prolonged use, in my opinion, the physician and patient should agree that the drugs are to be used without interruption, for years if necessary; until a profound remission of the disease appears to have occurred. Complete discontinuance is contraindicated since such a disease as rheumatoid arthritis may smoulder in a sub-clinical state, only to rebound in a severe exacerbation when even minimal medication is stopped. For example, when arthritis is suppressed, a small dosage is usually strong enough to maintain the suppression, but if this is removed, the smouldering disease flares up in greatly magnified force. This deliberate or ignorant induction of the rebound exacerbation is to be avoided at all costs. At the same time, the physician and patient should know that the dosage is not constant although administration is continuous.

It is advisable in starting the treatment of a chronic disease requiring medication for years, to titrate the benefit of very minimal amounts up to the smallest effective daily dosage. This is the reverse of the method of treating acute conditions in which immediate suppression of the inflammation is desired, and prompt, if graduated, complete hormone withdrawal is planned. In the chronic disease, the dosage will be increased as the disease waxes in severity and decreased as it becomes milder.

Most important in the chronic treatment regimen is the prescription of associated medications required to support biochemical, immunological and physiological homeostasis. These are as follows:

1. Prevention of negative potassium balance and hypokalemia. All the disorders known to result from this may be produced by cortisone medication. One of the chief of these is psychosis. Administration of from 3 to 15 grams (not grains) a day of potassium salts are required.
2. Prevention of cellular catabolism which results in the loss of nitrogen, calcium, potassium and other vital elements may be obtained by the administration of the anabolic sex hormone steroids, testosterone and estradiol or estrones.
3. Abnormal retention of sodium may occur with a dependent edema and hypertension. This can be controlled by a low salt diet and chlorothiazide or related derivatives.
4. Excessive gastric secretion of enzymes and acids which may produce gastric or duodenal ulcers must be neutralized by the usual but well-arranged anti-ulcer regimen: Milk feedings, on a time table by the clock to forestall the occurrence of symptoms; antacids; and effective anticholinergic drugs. In fact, if the patient is on higher dose levels of corticoids, he should routinely receive the full anti-ulcer program, just as if he already had an ulcer.
5. Most important is the anticipation of the spread of either acute or chronic bacterial infections; chest x-rays to detect a dissemination of tuberculosis should be taken at regular intervals. The onset of acute infections should be watched for with unusual alertness and prompt massive antibiotic therapy administered without delay.

The physician must realize that in employing cortisone or ACTH to prevent inflammation with its attendant pain, disability and deforming pathology, he is using an agent which has additional biochemical and physiological effects on all systems in the body. These cannot be ignored; they must be controlled if corticoids are to be used safely.

The multiplicity of the diseases that are presented in this book with the application of the corticoids and ACTH to their treatment is abundant proof of the enormous usage that can be made of these miracle drugs. Each chapter includes a bibliography of the references reviewed, which altogether give a wide survey of this field of therapeutic application.

PAUL STARR, M.D.

CONTENTS

Page

<i>Foreword</i>	v
<i>Chapter</i>	
1. ACTH AND ADRENOCORTICOSTEROID OUTPUT	3
Adrenocorticosteroid Output	3
Transport of Adrenocorticosteroids	8
Adrenocorticotrophic Hormone (ACTH) Output	8
2. COMPARISON OF CORTICOSTEROIDS	19
Natural Corticosteroids	19
Synthetic Corticosteroids	20
Fluorinated Cortisone and Hydrocortisone Derivatives	21
Prednisone and Prednisolone	21
Triamcinolone	25
6-Methylprednisolone	31
Dexamethasone	33
Summary and Conclusions	36
3. "ACTH: USEFUL IN THERAPY??"	48
Variations in Adrenocortical Response to ACTH	48
Allergic Reactions to ACTH	51
ACTH in Corticosteroid Synthesis	52
Extra-adrenal Actions of ACTH	53
Dermatologic Effects	54
Inconvenience	55
Summary and Conclusions	56
4. ENDOCRINE FUNCTION AFTER ACTH OR CORTICOSTEROID	
ADMINISTRATION	65
Evaluation of Adrenocortical Function after Corticosteroid	
Administration	68
Corticosteroid Withdrawal Syndrome	70

<i>Chapter</i>	<i>Page</i>
Prevention of Adrenal Suppression	72
Summary and Conclusions	73
5. CORTICOSTEROID EFFECT ON METABOLISM	79
Protein Metabolism	79
Carbohydrate Metabolism	82
Steroid Diabetes	84
Corticosteroid-Glucose Tolerance Tests	86
Influences on Diabetes Mellitus	88
Treatment of Hypoglycemia	91
Effect on Lipid Metabolism and Arteriosclerosis	92
Relation to Lipid Metabolism	93
Lipid Mobilizing Hormone	95
Electrolyte and Water Metabolism	97
Magnesium Metabolism	102
Control of Aldosterone Secretion	103
Secondary Aldosteronism	108
Primary Hyperaldosteronism	108
Corticosteroids and Hypertension	111
Calcium and Bone Metabolism	116
Uses of Corticosteroids in Disorders of Calcium and Bone Metabolism	117
Relation to Growth and Development	121
6. IMMUNOLOGICAL EFFECTS	149
Anti-inflammatory Action	149
Vascular Tone	149
Vascular Permeability	150
Phagocytosis	151
Anti-febrile Effect	152
Pro-inflammatory vs Anti-inflammatory Effects	153
The Role of ACTH and the Adrenocorticosteroids in Immunity	155
Relation to Plasma Antibody Reactions	156
Relation to Lymphocyte Antibody Reactions	160
Autoimmune Reactions and Tissue Antibodies	162

*Chapter**Page*

Relation to Histamine	163
Influence on Enzyme Systems	165
Eosinopenic Effects	166
Effects on Mesenchyme	169
Relations to Ascorbic Acid	171
7. UPPER GASTROINTESTINAL EFFECTS OF CORTICOSTEROIDS	190
Corticosteroids and Peptic Ulcers in Rheumatoid Disease	192
Adrenocorticosteroid Function and Peptic Ulcers	195
Variation in Incidence of Ulcers in Relation to Hormone Administered	196
Influence of Hormones on Healing of Peptic Ulcers	198
Variation in Gastroduodenal Disease Observed during Corticosteroid Therapy	199
Physiological Effects of the Corticosteroids on Upper Gastrointestinal Tract	201
Summary	211
8. HEPATOBILIARY AND SMALL INTESTINE EFFECTS	224
Corticosteroids in Liver Disorders	224
Metabolic Effects	224
Bilirubin Metabolism	225
Hormone Balance	225
Immune Reactions	226
Antitoxic Effects	227
Uses in Man	227
Altered Liver Function Due to Drugs	227
Viral Hepatitis	228
Primary Sclerosing Cholangitis	233
Primary Biliary Cirrhosis	233
Hemochromatosis	234
Constitutional Hepatic Dysfunction	234
Hepatic Cirrhosis	234
Pancreas	239
Theoretic Considerations	239
Uses in Pancreatic Disorders	240

<i>Chapter</i>	<i>Page</i>
Small Intestine	241
Malabsorption Syndromes	241
9. PSYCHIATRIC AND NEUROLOGIC EFFECTS OF CORTICOSTEROIDS	255
Neuropsychiatric Effects	255
Delirium Tremens	257
Relation to Other Agents Influencing the Psyche ..	258
Uses in Neurology	259
Encephalomyelitis	259
Guillain-Barre Syndrome	260
Radiculoneuritis	262
Multiple Sclerosis	263
Chorea	264
Hypsarhythmia	265
Cerebral Infarction	266
Mongolism	267
Heat Stroke	267
Cephalgia	268
Muscular Dystrophy	268
Myasthenia Gravis	269
Miscellaneous Uses	269
10. RELATIONSHIP TO OTHER ENDOCRINE GLANDS AND USES IN ENDOCRINE DISORDERS	279
Thyroid-Adrenal Relationships	279
Antibodies in Thyroid Conditions	281
Uses of Corticosteroids in Thyroid Disorders	282
Thymus	287
Uses in Adrenal Disorders	287
Adrenal Insufficiency	287
Pituitary-Adrenal-Gonadal Relations	294
Stein-Leventhal Syndrome	295
Secondary Sex Disturbances, Hirsutism	297
Pituitary Dwarfism	298
11. ANTI-ADRENOCORTICAL COMPOUNDS	308
12. RESPIRATORY—EFFECTS AND USES	314

<i>Chapter</i>	<i>Page</i>
Uses in Allergy	314
Upper Respiratory Tract Uses	316
Deafness	318
Bell's Palsy	318
Lethal Midline Granuloma	319
Other Uses	319
Dosage in Allergic Rhinitis and Dermatitis	319
Lower Respiratory Tract Uses	321
Bronchial Asthma	321
Pulmonary Emphysema	335
Pulmonary-eosinophilia Syndrome	337
Primary Pulmonary Eosinophilic Granuloma	338
Viral Respiratory Infections	339
Bronchitis and Bronchiolitis	339
Interstitial Pneumonitis	341
Alveolar-capillary Block	341
Berylliosis	344
Radiation Pneumonitis	345
Rheumatic Pneumonitis	346
Silicosis	347
Silo-filler's Disease	347
Farmer's Lung	348
Pulmonary Alveolar Proteinosis	349
Idiopathic Pulmonary Hemosiderosis	349
Idiopathic Pulmonary Hypertension	349
13. ROLE IN SARCOIDOSIS	363
Sarcoidosis with Hypercalcemia	366
Dosage and Duration of Therapy	370
14. ROLE IN CARDIOLOGY	375
Stokes-Adams Syndrome	376
Rheumatic Fever	377
Corticosteroids vs Salicylates, Other Drugs	380
Pericarditis, Post Cardiotomy, and Post Myocardial Infarction Syndromes	383

<i>Chapter</i>	<i>Page</i>
Coronary Artery Disease	385
Myocardial Infarction with Shock	386
Congestive Heart Failure	386
Shoulder-Hand Syndrome	388
Bacterial Endocarditis	389
15. INFLUENCE OF THE CORTICOSTEROIDS IN INFECTIONS	396
Indications for Corticosteroids in Infection	400
Adrenal Insufficiency	400
Vascular and Other Tissue Effects	402
Sensitivity Reactions	403
Bacterial Endotoxin	404
Inflammatory Disorders of the Female Organs	418
Tuberculosis	419
Pulmonary Tuberculosis	423
Meningeal Tuberculosis	429
Other Tuberculous Lesions	432
Leprosy	433
Syphilis	434
Use of Steroids in Human Syphilis	434
Studies in Animals	436
Amebiasis	437
Malaria	437
Various Helminthic Infections	438
Trichinosis	438
Schistosomiasis (Bilharziasis)	440
Cysticercosis (Pork Tapeworm)	440
Visceral Larva Migrans (Toxocara Canis)	441
Loaisis (Filaria)	441
Echinococcosis (Hydatid Disease)	441
Fungus Infections	441
Virus Infections	444
Varicella	445
Herpes Zoster	446
Mumps	447

<i>Chapter</i>	<i>Page</i>
Measles	450
Acute Polioencephalitis	451
Virus Encephalitis	451
Infectious Mononucleosis	452
Influenza	454
Lymphogranuloma Venereum	455
16. RHEUMATOID ARTHRITIS AND OTHER RHEUMATOID DISORDERS	482
Rheumatoid Arthritis	482
Usage in Other Rheumatoid Disorders	492
Rheumatoid Spondylitis	492
Psoriasis and Psoriatic Arthritis	492
Sjogren's Disease	494
Reiter's Syndrome	494
Behcet's Syndrome	495
Periodic Disease	495
Allergic Arthritis	496
Tietze's Syndrome	496
Gout	497
Osteoarthritis	498
Intra-articular Uses of Corticosteroids	499
17. COLLAGEN AND RELATED DISEASES	510
Lupus Erythematosus	514
Dermatomyositis	519
Scleroderma	521
Usage in Ulcerative Colitis	522
Indications	522
Complications Related to Steroids	525
Routes of Administration and Dosages	526
Usage Locally in Ulcerative Colitis	527
Regional Enteritis	528
Dosage	530
Periarteritis Nodosa	530
Temporal Arteritis	532
Anaphylactoid Vascular Purpura	533

<i>Chapter</i>	<i>Page</i>
Weber-Christian Disease	535
18. USAGE IN NEPHROSIS AND OTHER SELECTED NEPHROPATHIES	548
Introduction	548
Role of Corticosteroids	549
Dangers of Steroids	552
Addition of Other Measures	553
Hormone Dosage	554
19. PRECIS	561
Anti-inflammatory Effects	562
Immunologic Effects	564
Protein Metabolism	566
Growth and Development	566
Carbohydrate Metabolism	567
Fat Metabolism	567
Inter-endocrine Relationships	568
Blood Coagulation	568
Electrolyte and Fluid Balance	568
Calcium and Bone Metabolism	569
Gastrointestinal Effects	569
Neuropsychiatric Effects	570
Hypercorticism vs Steroid Withdrawal	571
<i>Index</i>	573

CORTICOSTEROIDS IN MEDICAL PRACTICE

By

MILAN L. BRANDON, M.D.

*Formerly Head of Allergy Clinic
U. S. Naval Hospital
San Diego, California*

With a Foreword by

PAUL STARR, M.D.



CHARLES C THOMAS • PUBLISHER
Springfield • Illinois • U.S.A.

Chapter 1

ACTH AND ADRENOCORTICOSTEROID OUTPUT

ADRENOCORTICOSTEROID OUTPUT

The normal daily adrenocorticosteroid output in man has been estimated to be the equivalent of 12.5 to 40 mg. hydrocortisone per day (1-3). The excretion of hydrocortisone metabolites or 17-hydroxycorticosteroids is about 20 to 30 per cent higher in men than in women (4). Hydrocortisone is the steroid found in highest concentration in human adrenal vein blood and adrenal tissue. Determinations of adrenal vein hydrocortisone levels have indicated the output of hydrocortisone to be about 21 mg. per day (5) and 34 mg. per day (6). The concentration of hydrocortisone in the human adrenal gland is 2.3 to 5.5 micrograms per gram of fresh tissue (7).

Corticosterone, or compound B, is the second most abundant adrenocorticosteroid (8-11). Isotope dilution studies using corticosterone-4-C14 have indicated that the ratio of concentration of hydrocortisone to corticosterone in human plasma is 15 to 1 in normal subjects (8). The ratio of hydrocortisone to corticosterone was 4 to 1 and 13 to 1 in other reports (12, 13). Identification and assay of corticosterone in human plasma by isotope dilution showed the average concentration of corticosterone for twenty normal subjects was 1.1 ± 0.3 microgram per 100 cc. plasma (8). The normal daily secretion of hydrocortisone is thus estimated to be 17 to 29 mg. per day, and of corticosterone 2 to 3 mg. per day (13, 14). Hydrocortisone and compound B make up from 85 to virtually 100 per cent of the total alpha-one-beta-unsaturated-3-ketosteroids in the adrenal venous blood of most species of common laboratory animals (15).

C14 labelled hydrocortisone has been administered intravenously in trace amounts to measure hydrocortisone turnover

rates and production on the basis that the metabolites of the labelled hormones enter equally into the urine with those of non-labelled hydrocortisone (14, 16). When the rates observed during periods of two to four hours were assumed to represent the rate of production throughout twenty-four hours, the rate of hydrocortisone production was estimated to be from 17 to 29 mg. per day, mean 21 mg. per day (14). When total twenty-four hour secretion was measured using C-14 labelled hydrocortisone in 12 quiescent and convalescent patients, a direct measurement of the total C14 content of the urine and the specific gravity of tetrahydrocortisone was determined (16). The average daily secretion of hydrocortisone was about 13.5 mg. in normal subjects with a range of variation of 5 to 28 mg. In six patients with severe active but non-endocrine disease the output was 10 to 32 mg. (average 20 mg.) per day (16). Very low levels of free and conjugated steroids are present in infants and children (17).

Plasma C17-21-hydroxycorticosteroid levels are elevated in pregnancy. Plasma levels of adrenocorticosteroids in pregnant women may reach 400 per cent of the levels in nonpregnant females (18). Similarities between pregnancy and Cushing's syndrome have been noted (19). However, increased adrenocortical activity in pregnancy manifests itself in a response of all sectors of the adrenal cortex (20). The 17-ketosteroids show moderate elevation during the first three months of pregnancy, and subsequently the 17-hydroxycorticoids, glycometabolic activity, and sodium retaining fractions are rapidly augmented (20). A further rise in steroid levels occurs during labor and delivery, reaching a maximum one hour after delivery, but by twenty-four hours post-partum the level is down to that present before active labor (21).

Some individuals have a normal baseline adrenocorticosteroid output but fail to respond with increased output to stress or to ACTH injections (22). When subjected to stress they may have manifestations of adrenal insufficiency. In patients with chronic illnesses the 17-ketosteroid output is not infrequently lowered as compared to healthy subjects (23, 24). Decreased adrenocortical responsiveness to ACTH has been observed in patients debilitated with cancer and other disorders (25, 26). The 17-

ketosteroid response is depressed in debilitated patients undergoing acute stresses, although there may be marked formaldehydogenic increases (27). Urinary adrenocorticosteroid output is usually lowered in chronic hepatic disease, which may be at least partly related to the fact that the liver appears to be the main site of metabolism of the hormones and because other endocrine alterations are not infrequently present in chronic hepatic dysfunction. Excretion of 17-ketosteroids has been noted to be significantly reduced with ageing, particularly the non-11-oxygenated steroids (28). Adrenal insufficiency may occur at times of stress and require small supplements of corticosteroids. Reduced tolerance to stress is more common in the older age groups and in debilitated patients who have had repeated operative procedures (29). The effect of age by itself on adrenal function has been questioned, however (30). Age induces no significant change in eosinophile response to ACTH (31). It has been suggested that the corticosteroids should be administered to elderly patients under circumstances where it is important to increase their general resistance including to protect them from surgical shock (32).

The General Adaptation Syndrome was described by Selye (33). The importance of the hypothalamic-pituitary-adrenal axis in participating in the reaction has been demonstrated (34, 35). Conditions of stress are frequently associated with increased plasma levels of 17-hydroxycorticosteroids (36, 37). The mechanism of such elevation is not definitely known. Cytologic changes in the human adrenal gland in patients dying from conditions associated with acute stress, or after exogenous administration of corticotropin are similar, which supports the view that the adrenal changes in stress are the result of an increase in endogenous corticotropin production (38).

Increased production of ACTH has been attributed to accelerated utilization of adrenal steroids in stress conditions, but there is evidence that the removal rate of hydrocortisone may be normal or decreased in stress. A normal or decelerated rate of cortisol metabolism has been observed in subjects with various diseases (23, 39), and a normal or decreased rate of metabolism of intravenously administered cortisol has been observed in man